Haleon plc: Director/PDMR Shareholding
22 November 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by a Person Discharging Managerial Responsibilities ("PDMR").
On 21 November 2024, Dawn Allen, Chief Financial Officer, received the vesting of an award of Haleon Ordinary Shares under the Haleon Share Value Plan. The award was granted as part of her remuneration arrangements upon joining Haleon, to compensate for forfeited incentives from her previous employment.
Immediately following vesting 74,678.928393 Ordinary Shares were sold to cover tax obligations at a price of £3.718 per share, with the remaining 83,974.071607 Ordinary Shares retained subject to a two-year holding period.
The award is subject to malus and clawback provisions.
Further details are set out in the below notification, made in accordance with the requirements of The UK Market Abuse Regulations.
|
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
|
| a)
| Name
| Dawn Allen | ||||
|
| 2
| Reason for the notification
| |||||
|
| a)
| Position/status
| Chief Financial Officer | ||||
|
| b)
| Initial notification /Amendment | Initial Notification | ||||
|
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
|
| a)
| Name
| Haleon plc | ||||
|
| b)
| LEI
| 549300PSB3WWEODCUP19 | ||||
|
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
|
| a)
| Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each | ||||
|
| | | |||||
|
| Identification code | GB00BMX86B70 | |||||
|
| | | |||||
|
| b)
| Nature of the transaction
| Acquisition of Ordinary Shares in respect of the Haleon plc Share Value Plan (Buyout award).
| ||||
|
| c)
| Price(s) and volume(s) | | | | | |
|
| | | | Price(s) | Volume(s) | | |
|
| | | | Nil | 158,653 | | |
|
| | | | | | ||
|
| d)
| Aggregated information | | ||||
|
| | | |||||
|
| - Aggregated volume | N/A | |||||
|
| | | |||||
|
| - Price | | |||||
|
| | | |||||
|
| e)
| Date of the transaction
| 21 November 2024 | ||||
|
| f)
| Place of the transaction
| Outside a trading venue
| ||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a)
| Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each | |||||
| | | ||||||
| Identification code | GB00BMX86B70 | ||||||
| | | ||||||
| b)
| Nature of the transaction
| Automatic disposal of Ordinary Shares resulting from the Haleon plc Share Value Plan (Buyout award) vesting to cover tax liabilities.
| |||||
| c)
| Price(s) and volume(s) | | | | | ||
| | | | Price(s) | Volume(s) | | ||
| | | | £3.718 | 74,678.928393 | | ||
| | | | | | |||
| d)
| Aggregated information | | |||||
| | | ||||||
| - Aggregated volume | N/A | ||||||
| | | ||||||
| - Price | | ||||||
| | | ||||||
| e)
| Date of the transaction
| 21 November 2024 | |||||
| f)
| Place of the transaction
| London Stock Exchange (XLON)
| |||||
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
